Search Results

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, reported its first-quarter 2024 financial results.

DermTech, Inc. announced that it will discontinue the optional TERT promoter mutation add-on assay for its DermTech Melanoma Test effective March 1, 2024.

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported positive topline results from its Trust 2 Study, which evaluated the foundational gene expression assay component of the DermTech Melanoma Test (DMT) in a real-world clinical setting.

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported positive topline results from a study evaluating the foundational gene expression assay component of the DermTech Melanoma Test (DMT) across all skin types in the real-world clinical setting.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, announced that effective March 27, 2024, the Compensation Committee of DermTech’s Board of Directors granted an aggregate of 26,240 restricted stock units to eight new employees under its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, reported its fourth-quarter 2023 financial results.

DermTech, Inc. will host a conference call and webcast on Thursday, February 29, 2024 at 5:00 p.m. Eastern Time (ET) to discuss the Company’s fourth-quarter 2023 operating and financial results.

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California.

DermTech, Inc. announced additional restructuring actions to prioritize revenue growth, streamline operations and further reduce overall operating expenses.